{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal allo-hMSCs",
            "NStudiesAvail": 430108,
            "NStudiesFound": 14,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 14,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Dileep Yavagal, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Temporarily not available"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [],
                        "NCTId": [
                              "NCT05522569"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 26, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "defined as a composite of acute suicidality, and hospitalization for suicide attempts."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of any treatment-emergent serious adverse events (TE-SAEs)"
                        ],
                        "NCTId": [
                              "NCT02675556"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Ihsan Salloum, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 23, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of any treatment-emergent serious adverse events, defined as a composite of acute suicidality and hospitalization for suicide attempts."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incident of treatment emergent-serious adverse events"
                        ],
                        "NCTId": [
                              "NCT03265808"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [
                              "Anthony Oliva, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Monitoring of events includes death, sustained/symptomatic ventricular tachycardia requiring intervention with inotropic support, aggravation of heart failure, new myocardial infarction, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Monitor major adverse cardiac events"
                        ],
                        "NCTId": [
                              "NCT02398604"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [
                              "David Kerman, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Evaluation of treatment emergent adverse events based on viability, safety and tolerance of the bone marrow-derived allogeneic mesenchymal stem cells implant (MSCs) in fistulizing Crohn's Disease patients, defined as:\n\nTreatment emergent adverse event (AE) rates, infections, hospitalizations or surgical interventions.\nPhysical examination\nVital signs\nLaboratory tests (biochemistry, hematology, urinalysis)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Evaluation of treatment emergent adverse events from the bone marrow-derived allogeneic mesenchymal stem cells implant"
                        ],
                        "NCTId": [
                              "NCT02677350"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "amendizabal@emmes.com"
                        ],
                        "PointOfContactOrganization": [
                              "The EMMES Corporation"
                        ],
                        "PointOfContactPhone": [
                              "301 251 1161"
                        ],
                        "PointOfContactPhoneExt": [
                              "221"
                        ],
                        "PointOfContactTitle": [
                              "Adam Mendizabal"
                        ],
                        "PrimaryCompletionDate": [
                              "April 2011"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation"
                        ],
                        "NCTId": [
                              "NCT01087996"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "JHare@med.miami.edu"
                        ],
                        "PointOfContactOrganization": [
                              "University of Miami, Miller School of Medicine - Interdisciplinary Stem Cell Institute (ISCI)"
                        ],
                        "PointOfContactPhone": [
                              "305-243-5579"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Joshua M Hare, MD"
                        ],
                        "PrimaryCompletionDate": [
                              "October 2, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of any treatment-emergent serious adverse events (SAE), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.\n\nSerum chemistry: chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, glucose, calcium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (fractionate if total >1.5 times normal), alkaline phosphatase, albumin,\nHematology (Complete blood count): hemoglobin, hematocrit, platelets, white blood cells (WBC), WBC differential"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)"
                        ],
                        "NCTId": [
                              "NCT02065245"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Andrew Sherman, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 1, 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence (at one-month post injection) of any treatment-emergent serious adverse events."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of any treatment-emergent serious adverse events"
                        ],
                        "NCTId": [
                              "NCT03487731"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [
                              "Matthias A Salathe, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2027"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences happening within the first 30 days after infusion."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of any treatment-emergent serious adverse event (TE-SAE)"
                        ],
                        "NCTId": [
                              "NCT03058068"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "jhare@med.miami.edu"
                        ],
                        "PointOfContactOrganization": [
                              "University of Miami"
                        ],
                        "PointOfContactPhone": [
                              "305-243-5579"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Dr. Joshua M. Hare, MD"
                        ],
                        "PrimaryCompletionDate": [
                              "August 26, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "TE-SAEs as evaluated by the investigator which may include but not limited to: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of Treatment Emergent Serious Adverse Events (TE-SAEs)"
                        ],
                        "NCTId": [
                              "NCT02886884"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OverallOfficialName": [
                              "Marilyn K. Glassberg, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 11, 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety (Primary): Incidence (one month post infusion) of any treatment-emergent serious adverse events (TE-SAEs), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To determine the safety and tolerability of intravenous allo hMSCs in patients with Idiopathic Pulmonary Fibrosis (IPF)."
                        ],
                        "NCTId": [
                              "NCT02013700"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "mpujol@med.miami.edu"
                        ],
                        "PointOfContactOrganization": [
                              "ISCI / University of Miami Miller School of Medicine"
                        ],
                        "PointOfContactPhone": [
                              "305-243-7273"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Marietsy pujol / Senior Regulatory Specialist"
                        ],
                        "PrimaryCompletionDate": [
                              "March 2, 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence (at one month post-catheterization) of any treatment-emergent serious adverse events, defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of Participants With Treatment-emergent Serious Adverse Events (SAE)."
                        ],
                        "NCTId": [
                              "NCT02013674"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "JHare@med.miami.edu"
                        ],
                        "PointOfContactOrganization": [
                              "ISCI / University of Miami Miller School of Medicine"
                        ],
                        "PointOfContactPhone": [
                              "305-243-5579"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Joshua M. Hare, MD"
                        ],
                        "PrimaryCompletionDate": [
                              "August 28, 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of TE-SAEs is defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise), or any other potential late effects detected and corroborated by clinical presentation, laboratory investigations, image analysis and when necessary with biopsy from suspected target sites in the body."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)"
                        ],
                        "NCTId": [
                              "NCT01392625"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OverallOfficialName": [
                              "Joshua Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Change in Left Ventricular Ejection Fraction (LVEF) as assessed via cardiac Magnetic Resonance Imaging (MRI)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change in LVEF"
                        ],
                        "NCTId": [
                              "NCT04476901"
                        ]
                  }
            ]
      }
}